Lybalvi olanzapine samidorphan manufacturer alkermes generic?

Question

Accepted Answer

Lybalvi (olanzapine + samidorphan) is a prescription medication approved for the treatment of schizophrenia in adults. It combines an atypical antipsychotic (olanzapine) with a μ‑opioid receptor antagonist (samidorphan) to help keep body weight from rising—a common side effect of olanzapine alone.

Item	Information
Manufacturer	Alkermes plc (UK‑based biopharma company). Alkermes holds the exclusive rights to Lybalvi and is responsible for its commercial distribution in the U.S., EU, Canada, Australia and many other markets.
Patent status	Lybalvi was approved by the FDA in 2021. The combination product is covered by a series of patents (e.g., “use of samidorphan with olanzapine to treat schizophrenia”) that generally protect the formulation for at least a decade from the approval date. Because of these patents, no fully generic version of the combination is currently on the market.
Generic availability	As of now (2026‑09) there is no approved generic Lybalvi in the U.S. or EU. The U.S. Food and Drug Administration (FDA) typically requires a biosimilar‑like generic approval pathway for combination products; however, the patents and the lack of a “generic equivalent” make it unlikely that a generic will appear until the patents expire. In other regions, generic availability may be dictated by local regulatory decisions and the expiration of the same patents.
What a generic would look like (theoretical)	A generic of the combination would need to contain the same olanzapine and samidorphan dose ratios, matching bioavailability, and the same formulation (e.g., 10 mg olanzapine + 0.75 mg samidorphan). It would also have to demonstrate equivalence in safety and efficacy. Because the patents are still active, any generic company would need to license the technology or wait until the exclusivity period lapses.
Alternatives	1. Olanzapine alone – available generically and on‑market, but without the samidorphan component. 2. Other antipsychotics – such as risperidone, quetiapine, aripiprazole, ziprasidone, etc., that may be less weight‑promoting. 3. Adjunctive weight‑management – diet, exercise, or weight‑management medications can help mitigate olanzapine‑induced weight gain.

Key Take‑aways

Alkermes is the sole manufacturer of Lybalvi.
A fully generic version of Lybalvi is not available yet; the product is still protected by active patents.
The next window for a generic entry will likely align with the expiration of the key patents (≈2027–2029, depending on jurisdiction).
For patients looking for a more cost‑effective option, olanzapine alone or other antipsychotics are alternatives, but they lack the samidorphan weight‑management benefit.

If you’re a prescriber or patient wondering about cost‑sharing, insurance coverage, or upcoming generic approvals, keeping an eye on FDA and EMA announcements is the best strategy. Feel free to let me know if you’d like more details on any of the alternatives or on how the patent landscape may change!

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Lybalvi olanzapine samidorphan manufacturer alkermes generic?

Key Take‑aways